HER2-TARGETED THERAPIES
Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy
In a study of 65 HER2-positive breast cancer patients receiving neoadjuvant trastuzumab, results demonstrate that the expression of serum miR-222-3p was the independent protective factor for trastuzumab-induced cardiotoxicity (p < .05) and anemia (p = .013), but that patients with low levels of miR-222-3p expression experienced superior disease-free survival (p = .029) and overall survival (p = .0037). The causes of these associations are not clear at this time.
Frontiers in Oncology
